期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
人参皂甙Rg3对实验性小鼠大肠肿瘤的预防作用 被引量:16
1
作者 丁小文 郑树 彭佳萍 《中华肿瘤防治杂志》 CAS 2006年第1期19-22,共4页
目的:研究人参皂甙Rg3对二甲肼(DMH)诱导的小鼠大肠肿瘤的预防作用及机制。方法:以DMH诱导小鼠大肠肿瘤,诱癌第8周起予以不同浓度Rg3,观察Rg3对大肠肿瘤的化学预防作用;免疫组化方法检测Rg3对小鼠肠肿瘤MVD的影响以及Rg3对VEGF蛋白的表... 目的:研究人参皂甙Rg3对二甲肼(DMH)诱导的小鼠大肠肿瘤的预防作用及机制。方法:以DMH诱导小鼠大肠肿瘤,诱癌第8周起予以不同浓度Rg3,观察Rg3对大肠肿瘤的化学预防作用;免疫组化方法检测Rg3对小鼠肠肿瘤MVD的影响以及Rg3对VEGF蛋白的表达影响。结果:相比于阳性对照组,不同浓度Rg3能够减少小鼠大肠癌发生率40%~50%,P<0.05;平均荷瘤数减少50%~60%,P<0.05;腺癌百分率减少30%~40%,P<0.05。相比于对照组(17.71±6.08),Rg3能够明显减少实验组小鼠肿瘤组织中的MVD(9.74±4.22),P<0.05。Rg3能够抑制小鼠肠肿瘤组织中VEGF蛋白的表达,P<0.05。结论:Rg3能够抑制DMH诱导的小鼠大肠肿瘤的发生,这种预防作用同Rg3对VEGF和MVD的抑制作用有关。 展开更多
关键词 人参皂甙 肠肿瘤/动物 实验 二甲基肼类 免疫组织化学
下载PDF
Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo 被引量:13
2
作者 Li-ZongShen Yi-BingHua Xue-MingYu QingXu TaoChen Jian-HuaWang Wen-XiWu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第7期1060-1064,共5页
AIM: To investigate the effect of tamoxifen (TAM) on multidrug resistance (MDR) of colorectal carcinoma in vivo and its relationship with estrogen receptor (ER). METHODS: Multidrug resistance was determined by means o... AIM: To investigate the effect of tamoxifen (TAM) on multidrug resistance (MDR) of colorectal carcinoma in vivo and its relationship with estrogen receptor (ER). METHODS: Multidrug resistance was determined by means of semi-quantitative retro-transcription polymerase chain reaction (RT-PCR) to test mdr1 gene mRNA and ER expression was studied by immunohistochemistry. Tumor tissues from three cases of human colon carcinoma, which had mdr1(+)/ER(+),mdr1(+)/ER(-), mdr1(-) expressions, were planted subcutaneously in the neck of nude mice to establish three xenograft models. These models were subdivided into four subgroups randomly: Doxorubicin (DOX)-treated group, TAM-treated group, DOX and TAM group and control group. The dimensions of these xenografts were measured after each course of treatment and the xenografts were removed at the end of the experiments for measurements of weight and the variation of mdr1 mRNA level with RT-PCR. In each course, TAM [15 mg/(kg/d)] was administrated orally per day in the first seven days and DOX (3.6 mg/kg) was injected peritoneally on the first day. Data was evaluated by q and t tests. RESULTS: In the animal models with mdr1(-) tumor, the weights and volumes of the planted tumor in DOX group [(39.1±2.29) mg, (31.44±1.61) mm3] and TAM and DOX group [(38.72±2.56) mg, (31.31v1.74) mm3], which were lesser than that of control group [(45.48±3.92) mg, (36.42±2.77) mm3, P= 0.037, P= 0.016 respectively] significantly. In the animal models with mdr1(+)/ER(+) tumor, the weights and volumes of planted tumor were not affected by DOX or TAM treatment; however, in TAM and DOX group [(425.5±28.58) mg, (340.35±22.28) mm3], they were significantly less than that of control group [(634.23±119.41) mg, (507.45±93.34) mm3, P= 0.022, P = 0.045 respectively], which are similar to that in the models with mdr1(+)/ER(-) tumor. No significant changes were found in the expressive level of mdr1 mRNA following these treatments. CONCLUSION: The expression of mdr1 gene corresponds to the sensitivity of colon cancer to anti-tumor drugs in vivo. TAM can reverse the MDR of colorectal carcinoma in nude mice, which is independent of the expression of ER; however, no change was observed in the expressive level of mdr1 mRNA. 展开更多
关键词 TAMOXIFEN Multidrug resistance Colorectal carcinoma Estrogen receptor
下载PDF
Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma 被引量:1
3
作者 Gui-PingLi Yong-XianWang +2 位作者 KaiHuang HuiZhang Chun-FuZhang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第13期1917-1921,共5页
AIM: To evaluate the influence of avidin chase on the side effects of radioimmunotherapy (RIT) in nude mice bearing human colon carcinoma and therapeutic outcome.METHODS: Purified anti-CEA monoclonal antibody (McAb)wa... AIM: To evaluate the influence of avidin chase on the side effects of radioimmunotherapy (RIT) in nude mice bearing human colon carcinoma and therapeutic outcome.METHODS: Purified anti-CEA monoclonal antibody (McAb)was biotinylated with NHS-biotin, and then radiolabeled with 188Re by the direct method. 188Re-labeledbiotinylated anti-CEA McAb (188Re-CEA McAb-Bt) was intravenously injected followed by intravenous injection of avidin after 24 h. SPECT imaging and biodistribution study were performed at 28-48 h after the injection of 188Re-CEA McAb-Bt. Three groups of nude mice subcutaneously grafted with human colon carcinoma were treated 7 d after the graft. Mice in the avidin chase group received intravenous injection of 188Re-CEA McAb-Bt (11.1 MBq/20 μg) followed by intravenous injection of cold avidin (80 μg) after 24 h. Mice in the control group (treated group without avidin chase) only received the injection of 188Re-CEA McAb-Bt (11.1 MBq/20 μg), another control group (non-treated group) only received 0.1 mL normal saline solution. Toxicity was evaluated on the basis of change of body weight and peripheral WBC counts, and therapy effects were determined by variation in tumor volume. Histological analysis of tumors was also performed.RESULTS: Avidin chase markedly accelerated the clearance of 188Re-CEA McAb-Bt from the blood and normal tissues. The tumor uptakes of 188Re-CEA Mc Ab-Bt at 28 h were 5.90 and 6.42% ID/g, respectively, in chase group and in non-chase group, while the tumor-to-background (T/NT) ratios were 3.19 and 0.56, respectively. The tumor uptake was slightly decreased by avidin chase, but the T/NT ratios were increased. In treated groups the growth rate of body weight and the number of WBC decreased after injection of 188Re-CEA McAb-Bt, and the WBC counts recovered earlier in the group with avidin chase than in the group without avidin chase. Compared to the nontreated group, treated groups with and without avidin chase showed significant anti-tumor effects.CONCLUSION: Avidin chase can effectively reduce the side effects of RIT, and improve therapeutic efficacy. 展开更多
关键词 Avidin chase RADIOIMMUNOTHERAPY Side effects Colon cancer Nude mice
下载PDF
Hypoestoxide inhibits tumor growth in the mouse CT26 colon tumor model
4
作者 Emmanuel A Ojo-Amaize Howard B Cottam +2 位作者 Olusola A Oyemade Joseph I Okogun Emeka J Nchekwube 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第34期4586-4588,共3页
AIM: To evaluate the effect of the natural diterpenoid, hypoestoxide (HE) on the growth of established colon cancer in mice. METHODS: The CT26.WT mouse colon carcinoma cell line was grown and expanded in vitro. Follow... AIM: To evaluate the effect of the natural diterpenoid, hypoestoxide (HE) on the growth of established colon cancer in mice. METHODS: The CT26.WT mouse colon carcinoma cell line was grown and expanded in vitro. Following the expansion, BALB/c mice were inoculated s.c. with viable tumor cells. After the tumors had established and developed to about 80-90 mm3, the mice were started on chemotherapy by oral administration of HE, 5-fluorouracil (5-FU) or combination. RESULTS: The antiangiogenic HE has previously been shown to inhibit the growth of melanoma in the B16F1 tumor model in C57BL/6 mice. Our results demonstrate that mean volume of tumors in mice treated with oral HE as a single agent or in combination with 5-FU, were significantly smaller (> 60%) than those in vehicle control mice (471.2 mm3 vs 1542.8 mm3, P < 0.01). The significant reductions in tumor burden resulted in pronounced mean survival times (MST) and increased life spans (ILS) in the treated mice. CONCLUSION: These results indicate that HE is an effective chemotherapeutic agent for colorectal cancer in mice and that HE may be used alone or in combination with 5-FU. 展开更多
关键词 Hypoestoxide 5-FLUOROURACIL Colon Cancer Mice
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部